Mok Yee Hui, Lee Jan Hau, Cheifetz Ira M
Children's Intensive Care Unit, Department of Paediatric Subspecialties, KK Women's and Children's Hospital, Singapore (Dr Mok and Dr Lee); Duke-NUS Graduate School of Medicine, Singapore (Dr Mok and Dr Lee); and Duke University Medical Center, Durham, North Carolina (Dr Cheifetz).
Adv Neonatal Care. 2016 Feb;16(1):26-36. doi: 10.1097/ANC.0000000000000244.
Extracorporeal membrane oxygenation (ECMO) can be deployed to support patients with severe cardiorespiratory failure unresponsive to conventional medical interventions. Neonatal trials have demonstrated that ECMO is an effective treatment of severe respiratory failure, with acceptable cognitive and functional outcomes. Technological advances in ECMO have resulted in improved safety and accessibility, contributing to decreased morbidity and improved survival of increasingly complex patients requiring ECMO support.
This review aims to describe the innovations in ECMO technology and management in the neonatal population in the last decade. The long-term outcomes of neonatal patients requiring ECMO support will be discussed.
Relevant clinical trials from MEDLINE and the Cochrane Library were identified. The following key words were used: ECMO, infant, neonate, and outcomes.
Challenges still remain in supporting the premature and/or low-birth-weight infant with severe respiratory failure, as well as infants with congenital diaphragmatic hernia. Neonatal ECMO survivors can present with neurodevelopmental and respiratory problems, which become more prominent with time.
While newer technologies have led to fewer neonates with respiratory failure progressing to ECMO, it remains an important tool to in those who have failed conventional therapies. Given the presence of neurodevelopmental problems in neonatal ECMO survivors, multidisciplinary follow-up targeting motor performance, exercise capacity, behavior, and subtle learning deficits is warranted.
With the overall decreasing use of neonatal ECMO, ECMO centers must find ways to maintain their expertise in the light of lower patient volumes amidst complex patient physiology.
体外膜肺氧合(ECMO)可用于支持对传统医学干预无反应的严重心肺功能衰竭患者。新生儿试验表明,ECMO是治疗严重呼吸衰竭的有效方法,具有可接受的认知和功能预后。ECMO技术的进步提高了安全性和可及性,有助于降低发病率,并提高了需要ECMO支持的日益复杂患者的生存率。
本综述旨在描述过去十年中新生儿群体ECMO技术和管理方面的创新。将讨论需要ECMO支持的新生儿患者的长期预后。
检索了MEDLINE和Cochrane图书馆的相关临床试验。使用了以下关键词:ECMO、婴儿、新生儿和预后。
在支持患有严重呼吸衰竭的早产儿和/或低体重儿以及先天性膈疝婴儿方面,挑战依然存在。新生儿ECMO幸存者可能会出现神经发育和呼吸问题,且随着时间推移会变得更加突出。
虽然新技术使因呼吸衰竭进展至ECMO的新生儿减少,但对于那些传统治疗失败的患者,它仍然是一项重要工具。鉴于新生儿ECMO幸存者存在神经发育问题,有必要针对运动表现、运动能力、行为和细微学习缺陷进行多学科随访。
随着新生儿ECMO总体使用量的减少,ECMO中心必须在患者数量减少且患者生理状况复杂的情况下,找到保持其专业知识的方法。